Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Assets: 2019-2025

Historic Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $439.8 million.

  • Allogene Therapeutics' Assets fell 25.35% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $439.8 million, marking a year-over-year decrease of 25.35%. This contributed to the annual value of $548.7 million for FY2024, which is 14.64% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Assets stood at $439.8 million, which was down 6.55% from $470.6 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Assets high stood at $1.2 billion for Q1 2021, and its period low was $439.8 million during Q3 2025.
  • In the last 3 years, Allogene Therapeutics' Assets had a median value of $589.1 million in 2024 and averaged $606.3 million.
  • Its Assets has fluctuated over the past 5 years, first surged by 71.24% in 2021, then decreased by 27.25% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Assets (Quarterly) stood at $1.1 billion in 2021, then decreased by 21.82% to $821.6 million in 2022, then dropped by 21.76% to $642.8 million in 2023, then dropped by 14.64% to $548.7 million in 2024, then fell by 25.35% to $439.8 million in 2025.
  • Its last three reported values are $439.8 million in Q3 2025, $470.6 million for Q2 2025, and $508.0 million during Q1 2025.